The New England journal of medicine
-
Randomized Controlled Trial Clinical Trial
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy--but not tamoxifen therapy of longer duration--prolongs disease-free and overall survival. The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy. ⋯ As compared with placebo, letrozole therapy after the completion of standard tamoxifen treatment significantly improves disease-free survival.